Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDOI Cancer Study of edoxaban in Italian adults with cancer-associated venous thromboembolism during antineoplastic therapy
2018-003833-14Phase 4Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of edoxaban in venous thromboembolism (VTE), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Impact of edoxaban-related adverse reactions on antineoplastic therapy. Started Jan 2021; status: completed.
02
Drugs
edoxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2018-003833-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003833-14.